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Abstract   
 Due to recent changes in federal and state legislations, the availability and 
consumption of cannabis products have increased in the United States. The expanded use 
of recreational and medicinal cannabis products increases the importance of 
implementing sensitive and selective instrumental methods in toxicological laboratories, 
as legal implications may arise in forensic cases, such as driving under the influence of 
drugs (DUID). The purpose of this study was to perform a cross-validation for the 
quantitative analysis of cannabinoids (Δ9-tetrahydrocannabinol, cannabidiol, cannabinol, 
11-hydroxy-Δ9-tetrahydrocannabinol, and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol) in 
serum by gas chromatography coupled to triple quadrupole tandem mass spectrometry 
(GCTQ). This method was fully validated following the Scientific Working Group for 
Forensic Toxicology (SWGTOX) standard practices for method validation in forensic 
toxicology. Linearity was established within 1-100 ng/ml; bias was within ± 20% and 
imprecision was less than 20%; limits of detection (LOD) and quantitation (LOQ) were 1 
ng/mL; and extraction efficiency ranged from 51.3 to 58.2%. Furthermore, the present 
method and a previously developed method for the determination of cannabinoids in 
blood were applied to serum (n = 20) and blood (n = 16) authentic case samples obtained 
from the New York City Office of the Chief Medical Examiner (NYC-OCME) to 
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Cannabis, also known as marijuana, is a psychoactive substance that is obtained 
from the Cannabis sativa plant (Levine, 2003; Negrusz & Cooper, 2013). Its main 
psychoactive component is Δ9-tetrahydrocannabinol (THC); however, the plant contains 
over 140 pharmacologically active cannabinoids, such as cannabidiol (CBD) and 
cannabinol (CBN) (Levinsohn & Hill, 2020). In the human body, THC metabolizes into 
11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC), which is the primary active 
metabolite, and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH), which is the 
primary inactive metabolite (Levine, 2003).   
Cannabis is the most commonly used illicit drug in the United States, with an 
estimated 43.5 million Americans aged 12 or older having reported using marijuana in 
2018 (Substance Abuse and Mental Health Services Administration, 2019). However, 
cannabis also has been increasingly used therapeutically; it is estimated that more than 
two million Americans utilize cannabis for therapeutic purposes (Levinsohn & Hill, 
2020). In regard to its clinical application, cannabis has been used to treat a variety of 
conditions, including multiple sclerosis, neuropathic pain, anxiety disorders, sleep 
disorders, appetite stimulation for HIV/AIDS patients, and nausea and vomiting due to 
chemotherapy (Citti, Braghiroli, Vandelli, & Cannazza, 2018). For example, Marinol® 
(dronabinol, a synthetic form of THC) and Cesamet® (nabilone, a derivative of THC) are 
medications that have been approved by the Food and Drug Administration (FDA) for the 
treatment of nausea and vomiting due to chemotherapy (Levinsohn & Hill, 2020). In 






for the treatment of drug-resistant seizures that result from Dravet syndrome or Lennox-
Gastaut syndrome (Kicman & King, 2014; Marcoux, Holmes, & Vogenberg, 2019).  
Currently, thirty-three states and the District of Columbia have enacted laws 
permitting the use of cannabis for medicinal purposes (Marcoux, Holmes, & Vogenberg, 
2019; Peterman, 2019). Of these thirty-three states, eleven states and the District of 
Columbia have legalized the use of cannabis for recreational purposes too (Levinsohn & 
Hill, 2020). Despite its medicalization and legalization in several states, cannabis remains 
classified as a Schedule I drug under the Controlled Substances Act because of its high 
potential for abuse and absence of a currently accepted medical use in the US. 
Nonetheless, the 2018 Farm Bill legalized the production of hemp containing less than 
0.3% of THC (Marcoux, Holmes, & Vogenberg, 2019).  
Cannabis is the most commonly detected illicit drug in driving under the influence 
of drugs (DUID) cases (Compton, 2017; Hartman, Richman, Hayes, & Huestis, 2016). 
Studies have concluded that cannabis impairs one’s driving ability due to its undesirable 
effects on reaction time, cognitive performance, divided attention, perception, and 
temporal and spatial orientation (Compton, 2017; Negrusz & Cooper, 2013). Specifically, 
slight driving impairment has been observed at THC serum concentrations between 2-5 
ng/mL, whereas significant driving impairment has been observed at THC serum 
concentrations between 5-10 ng/mL (Urfer, Morton, Beall, Feldmann, & Gunesch, 2014). 
Furthermore, cannabis use is associated with a significant dose-related decrease in 
driving performance and an increased number of traffic crashes (Hartman et al., 2016; 






 All states have enacted laws that prohibit individuals from driving while impaired 
by alcohol and/or other drugs (Compton, 2017). As of May 2019, eighteen states have 
enacted per se laws that prohibit an individual from driving with a specified amount of 
THC, which is commonly 5 ng/mL but ranges from 1-10 ng/mL in blood (Hartman et al., 
2016; Peterman, 2019). Other states have enacted zero tolerance laws that prohibit an 
individual from driving with any measurable amount of THC or its metabolites in the 
body (Compton, 2017). However, some studies have concluded that the concentration of 
THC and its metabolites in blood may not be an accurate and reliable predictor of the 
degree of impairment in an individual (Compton, 2017; Negrusz & Cooper, 2013; 
Peterman, 2019).  
The expanded use of recreational and medicinal cannabis products increases the 
importance of implementing sensitive and selective instrumental methods in toxicological 
laboratories, as legal implications may arise in DUID cases and other forensic cases. 
Although blood tests are often performed for the determination of cannabinoids in DUID 
cases, other biological matrices that are commonly examined include serum and plasma 
(Citti et al., 2018; Compton, 2017; Peterman, 2019). Nonetheless, equivalence among 
cannabinoid concentrations in blood, serum, and plasma has been scarcely explored 
(Giroud et al., 2001; Raikos et al., 2014; Schaefer et al., 2015; Schwilke et al., 2009). 
Solid phase extraction (SPE) or liquid-liquid extraction (LLE) followed by gas 
chromatography (GC) coupled to different types of detectors, such as the flame ionization 
detector (FID) and mass spectrometer (MS), has been traditionally employed for the 
simultaneous determination of cannabinoids in biological specimens (Gasse, Pfeiffer, 






Erdmann, & Veit, 2016; Schwilke et al., 2009). In addition, gas chromatography tandem 
mass spectrometry (GC-MS/MS) methods using electron impact or chemical ionization 
have been implemented to increase the sensitivity and specificity of the assay 
(Andrenyak, Moody, Slawson, O’Leary, & Haney, 2017; Castro, Tarelho, Melo, & 
Franco, 2018; Nahar et al., 2019). More recently, liquid chromatography mass 
spectrometry (LC-MS) and liquid chromatography tandem mass spectrometry (LC-
MS/MS) methods using electrospray ionization have been reported because they do not 
require derivatization (Citti et al., 2018; Gottardo, Sorio, Ballotari, & Tagliaro, 2019; 
Lacroix & Saussereau, 2012; Raikos et al., 2014; Schaefer et al., 2015; Schwope, 
Scheidweiler, & Huestis, 2011).  
The purpose of this study was to perform a cross-validation for the quantitative 
analysis of cannabinoids in serum by gas chromatography coupled to triple quadrupole 
tandem mass spectrometry (GCTQ). Furthermore, the present method and a previously 
developed method for the determination of cannabinoids in blood were applied to serum 
(n = 20) and blood (n = 16) authentic case samples obtained from the New York City 
Office of the Chief Medical Examiner (NYC-OCME) to investigate a correlation between 
cannabinoid concentration in serum versus blood. 
 
Materials and Methods 
1. Reagents and Supplies 
The certified reference materials for Δ9-tetrahydrocannabinol (THC, 1 mg/mL in 
methanol), Δ9-tetrahydrocannabinol-d3 (THC-d3, 1 mg/mL in methanol), cannabidiol 






tetrahydrocannabinol (11-OH-THC, 1 mg/mL in methanol), 11-hydroxy-Δ9-
tetrahydrocannabinol-d3 (11-OH-THC-d3, 100 µg/mL in methanol), 11-nor-9-carboxy-
Δ9-tetrahydrocannabinol (THC-COOH, 1 mg/mL in methanol), and 11-nor-9-carboxy-
Δ9-tetrahydrocannabinol-d9 (THC-COOH-d9, 1 mg/mL in methanol) were purchased 
from Cerilliant Corporation (Round Rock, TX, USA). HPLC-grade glacial acetic acid, 
ethyl acetate, deionized water (diH2O), ammonium hydroxide, and N,O-
Bis(trimethylsilyl)trifluoroacetamide (with 1% trimethylchlorosilane) were purchased 
from Thermo Fisher Scientific (Waltham, MA, USA). HPLC-grade hexane and LC/MS-
grade acetonitrile were purchased from Spectrum Chemical (New Brunswick, NJ, US).  
 Blank (drug-free) calf blood was obtained from O. Ottomanelli & Sons (New 
York, NY, US) for the preparation of the calibrator samples. Blank sheep serum was 
purchased from Hemostat Laboratories (Dixon, CA, US) for the preparation of the quality 
control (QC) samples. Hospital serum samples that previously screened negative for 
cannabinoids by the enzyme-linked immunosorbent assay (ELISA) were obtained from 
the NYC-OCME. Clean Screen Xcel II SPE columns were purchased from UCT, Inc. 
(Bristol, PA, US) and placed on a SPEware CEREX® System 48 processor for positive 
pressure SPE (Tecan, Männedorf, Switzerland). The eluent was evaporated under 
nitrogen using a SPEware CEREX® 48 Concentrator (Tecan, Männedorf, Switzerland). 
 
2. Instrumental Parameters 
 The analysis of cannabinoids in serum by GC-MS/MS was performed using an 
Agilent 7890B GC System equipped with an autosampler and connected to an Agilent 






CA, US).	 Chromatographic separation was accomplished using an Agilent DB17MS 
LTM column (15 m x 250 µm x 0.25 µm) and pre-column (1 m x 150 µm x 1.2 µm). The 
temperature of the LTM column started at 200°C and increased to 250°C over 6.5 min, 
remaining at 250°C for an additional minute of the run. Overall, the total run time was 
9.5 min in which the GC system equilibrated back to initial conditions during the final 
two minutes of the run.  
 The triple quadrupole mass spectrometer analyzed the compounds using electron 
impact (EI) ionization mode. The data were collected using multiple reaction monitoring 
(MRM) mode and processed using Agilent MassHunter Quantitative Analysis for QQQ. 
The instrumental parameters for the five target analytes and three internal standards were 
previously optimized by the Department of Forensic Toxicology at the NYC-OCME 
(Table 1). 11-hydroxy-Δ9-tetrahydrocannabinol-d3 (11-OH-THC-d3) and 11-nor-9-
carboxy-Δ9-tetrahydrocannabinol-d9 (THC-COOH-d9) were employed as the deuterated 
internal standards for 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-
carboxy-Δ9-tetrahydrocannabinol (THC-COOH), respectively. Δ9-tetrahydrocannabinol-
d3 (THC-d3) served as the internal standard for Δ9-tetrahydrocannabinol (THC), 











Table 1. MRM GC-MS/MS parameters for the derivatized target analytes and internal 









































































3. Preparation of the Calibrator and QC Samples 
 The working stock solution containing the five cannabinoids was prepared at 10 
mg/L in methanol. This solution was serially diluted to final concentrations of 0.1 and 1 
mg/L for a total of three working stock solutions for the calibrator samples. This 
procedure was repeated to create another set of working stock solutions for the QC 
samples. The internal standard solution containing the three deuterated internal standards 
was prepared at 0.5 mg/L in methanol. All these solutions were stored in a refrigerator at 
5°C when not in use. 
 
Table 2. Guidelines for the preparation of the calibrator and QC samples in 0.5 mL of 
biological sample (blood or serum). 







Calibrator 1 0.1 5 
5 0.1 25 
10 0.1 50 
25 1 12.5 
50 1 25 
80 1 40 
100 1 50 
QC 3 0.1 15 
20 1 10 
70 1 35 
 
 The mixed mode anion exchange SPE procedure required 0.5 mL of blank calf 






calibrator (1, 5, 10, 25, 50, 80, and 100 ng/mL) and QC (3, 20, and 70 ng/mL) samples 
were prepared by spiking the appropriate working stock solution into 0.5 mL of blank 
calf blood or sheep serum, respectively. The appropriate volumes of working stock 
solution for the calibrator and QC samples are presented in Table 2. 
 
4. Sample Extraction 
 The sample extraction procedure was based on the standard operating procedure 
(SOP) for the analysis of cannabinoids in blood by GC-MS/MS at the NYC-OCME. 
After fortifying the calibrator and QC samples with the appropriate volumes of working 
stock solution, 25 µL of 0.5 mg/L internal standard solution was added to all the tubes for 
a final concentration of 25 ng/mL. The samples were immediately vortexed using the 
Scientific Industries Vortex Genie Z (Scientific Industries Inc., Bohemia, NY, USA). 
Protein precipitation involved adding 1.5 mL of ice-cold acetonitrile to each sample 
dropwise while vortexing, followed by centrifugation at 3,000 rpm for 10 min. The 
acetonitrile was decanted into labeled 10 mL conical test tubes and evaporated under 
nitrogen to approximately 200 µL. After vortexing the samples, 2 mL of diH2O was 
added to all the tubes and the samples were vortexed again. The samples were decanted 
onto UCT Clean Screen Xcel II solid phase extraction cartridges that were placed on a 
positive pressure manifold, and passed through the column at 1-2 psi. Subsequently, the 
columns were washed with 2 mL of diH2O: acetonitrile: ammonium hydroxide (84:15:1, 
v/v) and dried for 10 min at 60 psi. The target analytes were eluted into labeled 16 x 125 
mm glass culture tubes with 2 mL of hexane: ethyl acetate: glacial acetic acid (49:49:2, 






samples were reconstituted with 50 µL of ethyl acetate and derivatized with 50 µL of 
BSTFA (with 1% TMCS). After capping and vortexing all the tubes, the samples were 
incubated for 30 min at 70° C. Finally, the derivatized extracts were transferred to labeled 
screw-capped vials with polymer feet inserts for GC-MS/MS analysis.  
 
5. Method Cross-Validation 
 The cross-validation for the analysis of cannabinoids in serum by GC-MS/MS 
was performed using the Scientific Working Group for Forensic Toxicology (SWGTOX) 
standard practices for method validation in forensic toxicology (Scientific Working 
Group for Forensic Toxicology, 2013). The reference methodology was the determination 
of cannabinoids in whole blood by GC-MS/MS, which was previously developed and 
validated at the NYC-OCME Forensic Toxicology Laboratory. The following parameters 
were assessed: bias, imprecision, limit of detection (LOD), limit of quantitation (LOQ), 
interferences, extraction efficiency, dilution integrity, and stability. The other validation 
parameters of calibration model and carryover were previously evaluated during the 
validation of cannabinoids in blood by GC-MS/MS at the NYC-OCME. 
 
a. Bias and Imprecision 
Bias and imprecision were concurrently evaluated by monitoring QC samples at 
3, 20, and 70 ng/mL over a course of five extractions with different calibration curves (n 
= 15). The maximum acceptable bias was not to exceed ± 20% at each QC concentration. 






one-way analysis of variation (ANOVA) approach, were not to exceed 20% at each QC 
concentration. 
 
b. Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
The LOD and LOQ were designated as the value of the lowest non-zero calibrator 
sample (1 ng/mL). Blank hospital serum samples from three different sources were 
analyzed using the criteria for detection, identification, bias, and imprecision. In order to 
meet the requirements for the LOD, the samples must produce a reproducible instrument 
response that is greater than 3x the signal-to-noise ratio (S/N) of the blank sample. For 
the LOQ, the samples must produce a reproducible instrument response that is greater 
than 10x the S/N of the blank sample, and result in bias not exceeding ± 20% and 
imprecision less than 20%.  
 
c. Interferences 
Endogenous interferences were studied by extracting blank serum samples from 
ten different sources without the addition of internal standard solution. Interferences from 
the reference standards were studied by fortifying blank serum samples with either the 
target analytes at the upper limit of the calibration range (100 ng/mL) or the internal 
standard solution, both in triplicate. Interferences from high concentrations of CBD were 
investigated by extracting a 500 ng/mL sample of CBD and monitoring its possible 








d. Extraction Efficiency 
 Extraction efficiency was evaluated by comparing the area responses of five QC 
samples to ten blank serum extracts with post-extraction cannabinoid addition. Extraction 
efficiency was evaluated at the low (3 ng/mL) and high (70 ng/mL) QC concentrations. 
 
e. Dilution Integrity 
 Dilution integrity was investigated by performing 1:2 and 1:5 dilution ratios of a 
150 ng/mL sample, both in triplicate, and evaluating their effects on bias.  
 
f. Stability 
The stability of the derivatized extracts was evaluated by re-injecting the low and 
high QC samples on the autosampler after 24, 48, and 72 h at room temperature. The 
percent differences between the initial and re-injected QC samples were calculated in 
which the maximum acceptable percent difference was not to exceed ± 20% at each QC 
concentration. 
 
6. Identification and Quantification Criteria 
 The criteria that were used for the identification of target analytes consisted of the 
following: the retention time must be within ± 2% of the average calibrator retention 
time, one quantifier and two qualifier product ions must be present, and the ion ratio 
qualifier/quantifier must be within ± 20% of the average calibrator ion ratios. In order to 
quantify the target analytes, the calibration curve for each target analyte must have an r2 






calibration points for a total of five calibration points to improve calibration curve 
linearity, calibrator or QC accuracy, or account for spiking or extraction issues in a 
specific calibrator sample.  
 
7. Authentic Case Sample Analysis 
 The NYC-OCME Forensic Toxicology Laboratory provided serum (n = 20) and 
blood (n = 16) authentic case samples for the analysis of cannabinoids by GC-MS/MS. 
These samples were selected because they previously screened positive for cannabinoids 
by ELISA during initial testing. In addition, these samples were submitted between 
January and May of 2019, and stored in vacutainer glass collection tubes in a refrigerator 
at 5°C when not in use. The blood sample sources included femoral (n = 1) and hospital 
blood (n = 15). Among these serum and blood authentic case samples, there were eight 
paired blood and serum samples that were collected at the same time at the hospital. The 
manner of death for these paired blood and serum samples included three accidental 
deaths, two homicides, and three natural deaths. Furthermore, these eight paired blood 




1. GC-MS/MS Method Cross-Validation in Serum 
 The analysis of cannabinoids in serum by GC-MS/MS demonstrated excellent 
sensitivity and selectivity in which all the target analytes were detected and quantified 







Figure 1. Total ion chromatogram (TIC) of a low QC (3 ng/mL) sample in sheep serum. 
The five target analytes eluted in the following order: CBD, THC, CBN, 11-OH-THC, 
and THC-COOH. 
 
 The cross-validation for cannabinoids in serum by GC-MS/MS was based on the 
previous validation for cannabinoids in blood by GC-MS/MS at the NYC-OCME. These 
methods were validated for the simultaneous quantification of five cannabinoids: THC, 
CBD, CBN, 11-OH-THC, and THC-COOH. The results from the cross-validation for 
cannabinoids in serum by GC-MS/MS are summarized in the following sections. 
 
a. Bias and Imprecision 
Bias and imprecision were concurrently evaluated by monitoring QC samples at 
the low (3 ng/mL), mid (20 ng/mL), and high (70 ng/mL) QC concentrations. All the 
target analytes showed acceptable bias (± 20%) and imprecision (< 20%), except for 
THC-COOH. Although THC-COOH failed the bias criteria with a bias of -27.6% at the 
mid QC concentration, it showed acceptable imprecision at each QC concentration. The 







Table 3. Summary of bias results at each QC concentration (3, 20, and 70 ng/mL) for the 




Low QC Mid QC High QC 
CBD -17.1 -19.8 -18.1 
THC -7.9 -11.3 -11.3 
CBN -13.8 -14.9 -17.1 
11-OH-THC -8.5 -9.4 -8 
THC-COOH 5.7 -27.6 7.4 
 
Table 4. Summary of imprecision results at each QC concentration (3, 20, and 70 ng/mL) 
for the target analytes in serum (n = 15). 
Compound 
Name 













CBD 9.6 5.5 9.6 6.1 10 6.4 
THC 7.2 4 6.2 3.8 4.9 3.2 
CBN 17.1 7.1 7.3 4 11.3 4.9 
11-OH-THC 6.4 2.7 5.4 3.3 4.9 3.1 
THC-COOH 12.4 5.3 14.4 7.9 6.9 3.1 
 
b. Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
At the LOD and LOQ (1 ng/mL), the bias results were within ± 20% of the target 
range (0.8-1.2 ng/mL) and the imprecision results were less than 20% for all the target 
analytes (Table 5). In addition to satisfying the identification criteria, each target analyte 







Table 5. Summary of bias and imprecision results at the LOD and LOQ (1 ng/mL) for 
the target analytes in serum (n = 9). 
Compound Name Bias (%) Imprecision (%CV) 
Intra-day Inter-day 
CBD -7.2 12 16.6 
THC -4.8 9.7 16.5 
CBN 5.2 5.4 9.7 
11-OH-THC -11.4 3.3 9.7 
THC-COOH 2.3 14.9 19.5 
 
c. Interferences 
 The presence of exogenous interferences from high concentrations of CBD was 
investigated by extracting a 500 ng/mL sample of CBD in triplicate. THC-COOH was 
detected in two replicates at 0.3 and 0.4 ng/mL. Similarly, THC-COOH was detected in 
all three replicates at concentrations ranging from 1.1-1.6 ng/mL during the validation of 
cannabinoids in blood by GC-MS/MS.  
 No matrix interferences were observed from the serum matrices used (n = 10). In 
addition, blank serum samples that were fortified with internal standard solution only did 
not produce positive results for the target analytes. However, 11-OH-THC-d3 was 
detected in two replicates of the blank serum samples that were fortified with the target 
analytes at the upper limit of the calibration range (100 ng/mL). The response of 11-OH-
THC-d3 was approximately 2-3.5% of its response when compared to samples that were 
fortified with internal standard solution too. Similarly, 11-OH-THC-d3 was detected in all 






d. Extraction Efficiency 
Extraction efficiency was evaluated by comparing the area responses of five QC 
samples to ten blank serum extracts with post-extraction cannabinoid addition. All the 
target analytes demonstrated optimal extraction efficiencies (> 50%), ranging from 51.3% 
for THC-COOH to 58.2% for CBN at the high QC (70 ng/mL) concentration (Table 6). 
However, the SPE procedure, poor derivatization, and protein precipitation step could 
have contributed to the reduced recovery of the target analytes. 
 
Table 6. Summary of extraction efficiency results at the low (3 ng/mL) and high (70 
ng/mL) QC concentrations for the target analytes in serum (n = 5). 
Compound Name Extraction Efficiency (%) 
Low QC High QC 
CBD 53.9 56.5 
THC 52.3 57.1 
CBN 54.3 58.2 
11-OH-THC 57.6 54.9 
THC-COOH 57.5 51.3 
 
e. Dilution Integrity 
Dilution integrity was investigated by performing 1:2 and 1:5 dilution ratios of a 
150 ng/mL sample, both in triplicate, and evaluating their effects on bias. When the 
dilution factors of 2 and 5 were applied on Agilent MassHunter Quantitative Analysis for 
QQQ, the average concentrations of CBD and CBN fell below the target range (120-180 
ng/mL). In contrast, the average concentrations of THC, 11-OH-THC, and THC-COOH 






Table 7. Summary of dilution integrity results for the target analytes in serum (n = 3). 
The concentrations should be within ± 20% of the target concentration (120-180 ng/mL). 
Compound Name Average Concentration (ng/mL) 
1:2 Dilution Ratio 1:5 Dilution Ratio 
CBD 88.1 89.9 
THC 123.4 123.1 
CBN 104.9 108.2 
11-OH-THC 126.4 124.3 
THC-COOH 140.8 136 
 
f. Stability 
 The stability of the derivatized extracts was evaluated by comparing the percent 
differences between the initial and re-injected low and high QC samples on the 
autosampler after 24, 48, and 72 h at room temperature. All the target analytes had 
percent differences less than 20%, except for THC. THC showed percent differences ≥ -
21.4% at the high QC concentration (70 ng/mL) after 24 h on the autosampler and ≥ -
20.9% at the low QC concentration (3 ng/mL) after 48 h on the autosampler. Therefore, 
samples that are on the autosampler for at least 24 h are not expected to provide 
consistent concentrations as compared to initial injections.  
 
2. Comparison of Validation Parameters in Serum vs. Blood 
 All the validation parameters that were assessed during the cross-validation in 
serum were previously evaluated during the validation in blood by GC-MS/MS. Overall, 






the main differences between the results from the cross-validation in serum and 
validation in blood by GC-MS/MS at the NYC-OCME. 
 
a. Calibration Curve Linearity 
 The calibration models for the target analytes were previously established during 
the validation of cannabinoids in blood by GC-MS/MS at the NYC-OCME. The 
calibration models were evaluated within the range of 1-100 ng/mL by fortifying blank 
calf blood samples with the appropriate volumes of working stock solution over a course 
of five extractions. The calibration models that best fit the data by having the lowest 
standard deviation of residuals are summarized in Table 8.  
 














CBD 1-100 1/x2 0.9928 0.2 6.8162 11 
THC 1-100 1/x 0.997 0.3 0.9564 5.7 
CBN 1-100 1/x2 0.9962 0.2 31.428 5.8 
11-OH-
THC 
1-100 1/x 0.9969 0.3 1.0137 5.9 
THC-
COOH 
1-100 1/x2 0.9947 0.3 1.1674 6.1 
 
b. Bias and Imprecision 
 As depicted in Table 3, THC-COOH failed the bias criteria with a bias of -27.6% 






showed acceptable bias during the validation of cannabinoids in blood. In addition, the 
imprecision results for all the target analytes were similar in both biological matrices. 
 
c. Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
 At the LOD and LOQ (1 ng/mL), the bias results were within the target range 
(0.8-1.2 ng/mL) and the imprecision results were less than 20% for all the target analytes 
in serum. In addition, each target analyte produced a reproducible instrument response 
that was greater than 10x the S/N of the blank sample. During the validation of 
cannabinoids in blood, THC-COOH failed the bias criteria with a bias of 34.3% but 
presented acceptable imprecision and S/N.  
 
d. Extraction Efficiency 
 As depicted in Table 6, all the target analytes demonstrated extraction efficiencies 
(> 50%) at the low (3 ng/mL) and high (70 ng/mL) QC concentrations in serum. All the 
target analytes exhibited lower extraction efficiencies in blood, ranging from 22.8% for 
THC-COOH at the high QC concentration (70 ng/mL) to 45.4% for CBD at the low QC 
concentration (3 ng/mL). Although this validation parameter did not have specific pass or 
fail criteria, the results suggest that this extraction procedure recovers the target analytes 









Table 9. Comparison of extraction efficiency results at the low (3 ng/mL) and high (70 
ng/mL) QC concentrations for the target analytes in blood and serum (n = 5). 
Compound 
Name 
Extraction Efficiency (%) 
Blood Serum 
Low QC High QC Low QC High QC 
CBD 45.4 42.3 53.9 56.5 
THC 36.2 35.3 52.3 57.1 
CBN 33.9 35.1 54.3 58.2 
11-OH-THC 35.2 32.9 57.6 54.9 
THC-COOH 27.4 22.8 57.5 51.3 
 
e. Dilution Integrity 
The dilution integrity results suggest that sample dilution in blood provides more 
accurate and reliable quantitative results for all the target analytes. In contrast to the 
results presented in Table 7, the average concentrations for all the target analytes were 
within the target range (120-180 ng/mL) during the validation of cannabinoids in blood.  
 
f. Stability 
 The stability results indicate that the derivatized extracts were more stable in 
blood than serum when left on the autosampler after given time intervals at room 
temperature. During the validation of cannabinoids in blood, all the target analytes had 
percent differences within ± 20%, except for CBN with a percent difference of 20.9% at 









3. Authentic Case Sample Analysis 
 Overall, 20 serum samples and 16 blood samples were analyzed for cannabinoids 
by GC-MS/MS. The most commonly detected target analyte was THC-COOH, which 
was detected in all the serum and blood samples. THC and 11-OH-THC were detected in 
one serum sample and six blood samples, CBD was detected in one blood sample, and 
CBN was not detected in either biological matrix. Figures 2 and 3 illustrate the overall 
trend of the target analytes being more frequently detected in blood than serum. 
 
 
Figure 2. Total ion chromatogram (TIC) of serum sample from case number 7. THC-
COOH (3.2 ng/mL) was detected. 
 
 
Figure 3. Total ion chromatogram (TIC) of hospital blood sample from case number 7. 








 Table 10 provides the range and median concentrations for the target analytes that 
were detected in the serum (n = 20) and blood (n = 16) authentic case samples. Target 
analytes that were detected at concentrations less than the LOD and LOQ (1 ng/mL) were 
not included in these results. 
 
Table 10. Summary of target analyte concentrations in blood (n = 16) and serum (n = 20) 
authentic case samples.  
Compound 
Name 
Statistics Blood (ng/mL) Serum 
(ng/mL) Femoral Hospital 




# of Cases 1 
THC Range 4.6 1.8 – 7.7 2.5 
Median 2 
# of Cases 1 5 1 
CBN ----- ----- ----- ----- 
11-OH-THC Range 1.8 1.3 – 3.2 1.5 
Median 2.1 
# of Cases 1 5 1 
THC-COOH Range >100 2.5 – >100 2 – >100 
Median 21.1 9 
# of Cases 1 15 20 
 
 Furthermore, the ratio of THC-COOH concentration in blood to serum was 
calculated for each paired blood and serum authentic case (n = 8). The average blood-to-
serum ratio was 2.1, which indicates that THC-COOH was generally detected at higher 






three paired blood and serum authentic cases, which demonstrates that THC-COOH was 
detected at higher concentrations in serum than blood too. As illustrated in Figure 4, no 
strong correlation was observed between the different matrix concentrations for THC-
COOH. 
 
Table 11. Ratio of THC-COOH concentration in blood to serum from paired blood and 
serum authentic cases (n = 8). 
Statistics Blood-to-Serum Ratio 
Mean 2.1 
Standard Deviation 1.8 
Range 0.4 – 5.6 
 
	
Figure 4. Scatter plot of THC-COOH concentration in serum versus blood from paired 









 Compared to the methods that are currently published in the literature, the present 
method requires a small volume of serum sample (0.5 mL) and encompasses a 
comprehensive working range of 1-100 ng/mL for these five target analytes (Citti et al., 
2018; Gottardo et al., 2019). All the target analytes presented acceptable bias and 
imprecision, except for THC-COOH at the mid QC concentration (20 ng/mL). This is not 
considered a major concern for the quantification of THC-COOH because its bias results 
were within ± 20% at the other QC concentrations, its precision results were less than 
20%, and it did not affect the other validation parameters. Although some methods utilize 
lower LOD and LOQ values, this is not critical because the cut-offs for initial and 
confirmatory testing of cannabinoids in blood require analytical results as low as 1 
ng/mL, which is the value of the LOD and LOQ for the present method. 
  The interferences that resulted from fortifying blank serum samples with either a 
high concentration of CBD or the target analytes at the upper limit of the calibration 
range (100 ng/mL) were also present during the validation of cannabinoids in blood by 
GC-MS/MS, and are not expected to interfere with the assay. The dilution integrity 
results suggest that sample dilution in blood provides more accurate and reliable 
quantitative results for all the target analytes. In addition, the stability results suggest that 
THC is unstable in serum when left on the autosampler at room temperature. In contrast, 
studies have reported that THC remains stable in serum when left on the autosampler 
after 24 h (Gasse et al., 2016; Purschke et al., 2016). Nonetheless, the stability results for 
THC were very close to the maximum acceptable percent difference (± 20%). Perhaps, 






THC (Andrenyak et al., 2017). Furthermore, all the target analytes demonstrated greater 
extraction efficiencies in serum than blood.  
 Although THC-COOH was detected in all the serum and blood authentic case 
samples, the other target analytes were more commonly detected in blood than serum. 
The ratio of THC-COOH concentration in blood to serum was calculated for the eight 
paired blood and serum authentic cases to identify a correlation between the different 
biological matrices. Similarly, Giroud et al. (2001) calculated the ratios of THC, 11-OH-
THC, and THC-COOH concentrations in plasma or serum to whole blood for eight paired 
plasma and whole blood cases and six paired postmortem blood and serum cases. Their 
results were similar in that THC-COOH was detected in all the samples, followed by 
THC and then 11-OH-THC. However, they concluded that these cannabinoids were 
detected at higher concentrations in plasma and serum than whole blood.  
 Moreover, studies have concluded that cannabinoid concentrations are greater in 
serum than whole blood due to high plasma protein binding and poor cannabinoid 
distribution in erythrocytes (Giroud et al., 2001; Schwilke et al., 2009; Urfer et al., 2014). 
The current project produced mixed results in which the ratio of THC-COOH 
concentration in blood to serum ranged from 0.4-5.6. Further research with a larger 
sample size is necessary to elucidate cannabinoid distribution in blood and serum. Other 
important parameters that should be considered include storage temperature and the type 
of collection tubes used for the hospital serum and blood samples. These factors may 
influence the stability of cannabinoids in biological samples, and therefore explain the 








 The cross-validation for cannabinoids in serum by GC-MS/MS was performed 
based on the previous validation for cannabinoids in blood by GC-MS/MS at the NYC-
OCME. These methods involved SPE followed by GCTQ for the simultaneous 
quantification of CBD, THC, CBN, 11-OH-THC, and THC-COOH. In addition, they 
were applied to serum (n = 20) and blood (n = 16) authentic case samples obtained from 
the NYC-OCME to investigate cannabinoid distribution in serum and blood. Lastly, the 
present method is important for forensic cases that require a high degree of sensitivity 
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Appendix A: Acronyms and Abbreviations 
11-OH-THC  11-hydroxy-Δ9-tetrahydrocannabinol 
ANOVA  Analysis of Variance 
CBD   Cannabidiol 
CBN   Cannabinol 
CV   Coefficient of Variation 
DUID   Driving Under the Influence of Drugs 
EI   Electron Impact 
GC   Gas Chromatography 
GC-MS   Gas Chromatography Mass Spectrometry 
GC-MS/MS  Gas Chromatography Tandem Mass Spectrometry 
GCTQ Gas Chromatography Coupled to Triple Quadrupole Tandem Mass 
Spectrometry  
LC-MS  Liquid Chromatography Mass Spectrometry 
LC-MS/MS  Liquid Chromatography Tandem Mass Spectrometry 
LLE   Liquid-Liquid Extraction 
LOD   Limit of Detection 
LOQ   Limit of Quantitation 
MRM   Multiple Reaction Monitoring 
MS   Mass Spectrometer 
NYC-OCME  New York City Office of Chief Medical Examiner 






S/N   Signal-to-Noise 
SOP   Standard Operating Procedure 
SPE   Solid Phase Extraction 
SWGTOX  Scientific Working Group for Forensic Toxicology 
THC   Δ9-tetrahydrocannabinol 
THC-COOH  11-nor-9-carboxy-Δ9-tetrahydrocannabinol 






























































Comments Blood Serum 
1 THC 7.7 Not Detected Hospital 
Blood 
 
11-OH-THC 3.2 Not Detected 
THC-COOH 38.9 12.9 
2 THC Not Detected 2.5 Hospital 
Blood 
 
11-OH-THC Not Detected 1.5 
THC-COOH 44.8 89.1 
3 THC-COOH > 100 28.9 Hospital 
Blood 
Suicide 
4 THC-COOH N/A 1.9 N/A  
5 THC-COOH 2.5 4.4 Hospital 
Blood 
 
6 THC-COOH N/A 6.3 N/A  
7 THC 1.8 Not Detected Hospital 
Blood 
 
11-OH-THC 1.4 Not Detected 
THC-COOH 8.8 3.2 
8 THC-COOH 4.9 3.4 Hospital 
Blood 
 
9 THC-COOH 3.4 9.6 Hospital 
Blood 
 
10 THC-COOH 35.1 79.7 Hospital 
Blood 
 
11 CBD 1.2 Not Detected Femoral  
THC 4.6 Not Detected 
11-OH-THC 1.8 Not Detected 
THC-COOH > 100 > 100 
12 THC-COOH N/A 8.5 N/A  
13 THC-COOH N/A 28.4 N/A  
14 THC 2.3 Not Detected Hospital 
Blood 
 






THC-COOH 47.6 32.4 
15 THC-COOH 21.1 5.3 Hospital 
Blood 
 
16 THC-COOH 5.5 4.2 Hospital 
Blood 
 
17 THC-COOH 16.4 4.9 Hospital 
Blood 
 
18 THC 1.9 Not Detected Hospital 
Blood 
 
11-OH-THC 1.3 Not Detected 
THC-COOH 23.9 36.6 
19 THC-COOH 8.7 6.7 Hospital 
Blood 
 
20 THC 2 Not Detected Hospital 
Blood 
 
11-OH-THC 2.2 Not Detected 
THC-COOH 54.9 9.8 
 
